



# New Hampshire Medicaid Fee-for-Service (FFS) Program

## Prior Authorization Drug Approval Form

Crenessity™ (crinecerfont)

DATE OF MEDICATION REQUEST:     /     /

### SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

MEDICAID ID NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

DATE OF BIRTH:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

GENDER: ☐ Male ☐ Female

Drug Name

Strength

Dosing Directions

Length of Therapy

### SECTION II: PRESCRIBER INFORMATION

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SPECIALTY:

NPI NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PHONE NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FAX NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

### SECTION III: CLINICAL HISTORY

1. Is the patient 4 years of age and older? ☐ Yes ☐ No
2. Does the patient have a diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency? ☐ Yes ☐ No  
If yes, identify how diagnosis was confirmed. (Select all that apply.)
  - ☐ Positive infant screening with secondary tier 2 confirmatory testing
  - ☐ Elevated serum 17-hydroxyprogesterone level (17OHP) above upper limit of normal
  - ☐ Cosyntropin (adrenocorticotrophic hormone [ACTH] stimulation test
  - ☐ Genetic testing for mutation in the CYP21A2 gene consistent with CAH
3. Does the patient have hypersensitivity to Crenessity™ or any excipients of the product? ☐ Yes ☐ No
4. Is the patient currently receiving glucocorticoid replacement therapy? ☐ Yes ☐ No
5. Will the patient continue glucocorticoid treatment at a dosage required for replacement therapy? ☐ Yes ☐ No

Phone: 1-866-675-7755

Fax: 1-888-603-7696

© 2025 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

Revision Date: 11/01/2025





**New Hampshire Medicaid Fee-for-Service (FFS) Program**  
**Prior Authorization Drug Approval Form**  
Crenessity™ (crinecerfont)

**PATIENT LAST NAME:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**PATIENT FIRST NAME:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

6. Is the prescriber an endocrinologist or geneticist, or has the prescriber consulted with a specialist in congenital adrenal hyperplasia? ☐ Yes ☐ No
7. Is there any additional information that would help in the decision-making process?  
If additional space is needed, please use a separate sheet.

**SECTION IV: RENEWAL**

1. Has the patient had clinical benefit with the use of Crenessity™? ☐ Yes ☐ No
2. Has the patient experienced any treatment-restricting adverse effects? ☐ Yes ☐ No

**I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.**

**PRESCRIBER'S SIGNATURE:** \_\_\_\_\_ **DATE:** \_\_\_\_\_